# KLF6

## Overview
KLF6, or Krüppel-like factor 6, is a gene that encodes a zinc finger transcription factor involved in the regulation of various cellular processes, including proliferation, differentiation, and apoptosis. The KLF6 protein is a member of the Krüppel-like family of transcription factors, characterized by its three C2H2 zinc finger motifs that facilitate DNA binding to specific promoter regions (Syafruddin2020Two; Andreoli2010Biology). This transcription factor is expressed in multiple tissues and plays a critical role in embryonic development, particularly in placental development and yolk sac vascularization (Andreoli2010Biology; Dionyssiou2013Krüppellike). KLF6 is also implicated in tumor suppression, with its inactivation frequently observed in various cancers, including hepatocellular carcinoma and prostate cancer (DiFeo2009The; KremerTal2004Frequent). The gene undergoes alternative splicing, resulting in isoforms such as KLF6-SV1, which are associated with oncogenic activity (DiFeo2009The). Through its interactions with other transcription factors and involvement in key signaling pathways, KLF6 plays a multifaceted role in cellular regulation and has significant implications in cancer pathogenesis (Syafruddin2020Two; Calderon2012Liganddependent).

## Structure
The KLF6 protein is a member of the Krüppel-like family of transcription factors, characterized by a modular structure typical of transcription factors. It contains three C2H2 zinc finger motifs in its C-terminal domain, which are crucial for DNA binding, specifically to GC-box or CACCC motifs in DNA promoter regions (Syafruddin2020Two; Andreoli2010Biology). These zinc finger motifs form a β-hairpin followed by an α-helix, contributing to the protein's tertiary structure (Syafruddin2020Two).

The N-terminal domain of KLF6 is acidic and interacts with various transcription factors and cofactors, such as Sp1, KLF4, and p53, to regulate transcription (Syafruddin2020Two). The central domain is rich in serine and threonine residues, making it a target for phosphorylation, a common post-translational modification for KLF6. Phosphorylation sites include T147, S150, S151, S171, S192, and S233 (Syafruddin2020Two; Andreoli2010Biology).

KLF6 undergoes alternative splicing, resulting in several isoforms, including KLF6-SV1, which lacks the zinc finger DNA binding domains and is associated with oncogenic activity (DiFeo2009The; Liang2014Identification). The full-length KLF6 localizes to the nucleus, while some splice variants, like KLF6-SV1, are mislocalized to the cytoplasm (Rodríguez2010NucleoCytoplasmic).

## Function
KLF6 (KLF transcription factor 6) is a zinc finger DNA-binding protein that plays a crucial role in regulating various cellular processes in healthy human cells. It is involved in cell proliferation, differentiation, metabolism, apoptosis, and inflammation (Syafruddin2020Two). KLF6 is expressed in multiple tissues, including the liver, leukocytes, and placenta, where it was initially identified as a core promoter-binding protein (Syafruddin2020Two; Andreoli2010Biology).

In the nucleus, KLF6 acts as a transcriptional regulator by binding to GC-boxes or CACCC elements in the promoters of target genes (Dionyssiou2013Krüppellike). It interacts with other transcription factors such as Sp1, KLF4, and p53, influencing both activation and repression of gene expression (Andreoli2010Biology). KLF6 is involved in the transcriptional regulation of genes related to cellular injury response and tissue repair, including transforming growth factor beta 1 (TGFβ1) and collagen type 1 alpha 1 (COL1A1) (Syafruddin2020Two).

KLF6 is essential for normal embryonic development, particularly in placental development and yolk sac vascularization, as evidenced by the early lethality of KLF6 knockout models (Andreoli2010Biology; Dionyssiou2013Krüppellike). It also plays a role in hematopoiesis and the development of endoderm-derived organs like the liver (Syafruddin2020Two).

## Clinical Significance
Mutations and alterations in the KLF6 gene are implicated in various cancers. KLF6 functions as a tumor suppressor, and its inactivation is frequently observed in cancers such as hepatocellular carcinoma (HCC), where loss of heterozygosity and somatic mutations are common (KremerTal2004Frequent). In prostate cancer, KLF6 is often inactivated, aligning with Knudson's two-hit hypothesis, and a germline polymorphism is linked to increased cancer risk due to higher expression of the oncogenic splice variant KLF6-SV1 (Syafruddin2020Two; DiFeo2009The). KLF6-SV1 is overexpressed in several cancers, including prostate, lung, and ovarian cancers, and is associated with poor prognosis (DiFeo2009The).

In gastric cancer, KLF6 mutations such as R71Q and S180L lead to increased tumorigenicity and decreased cellular differentiation, with a high frequency of allelic loss and somatic mutations observed (Sangodkar2009Functional). KLF6 is also implicated in astrocytic gliomas, where mutations are found in a subset of cases, supporting its role as a tumor suppressor (Jeng2003KLF6). Additionally, KLF6 expression is upregulated in acute myeloid leukemia, promoting leukemia development (Syafruddin2020Two). These findings highlight the clinical significance of KLF6 in cancer pathogenesis.

## Interactions
KLF6, a zinc finger transcription factor, engages in various protein interactions that influence its role in gene regulation and tumor suppression. It interacts with the ligand-dependent corepressor (LCoR), forming a complex that represses the transcription of the CDKN1A gene, which encodes the cell cycle regulator p21 WAF1/CIP1. This repression involves the recruitment of C-terminal binding proteins (CtBPs) and histone deacetylases (HDACs) to the promoters of target genes (Calderon2012Liganddependent). KLF6 also binds to cyclin D1, inhibiting the cyclin D1/cdk4 complex, which reduces phosphorylation of the retinoblastoma (Rb) protein, thereby controlling cell cycle progression (Benzeno2004CyclinDependent).

KLF6 interacts with other transcription factors such as Sp1 and KLF4, modulating DNA-binding specificity and influencing cellular processes (DiFeo2009The). It also acts as a coactivator for NF-κβ, influencing the expression of proinflammatory cytokines and regulating macrophage polarization (Syafruddin2020Two). Additionally, KLF6 is involved in the transcriptional activation of TGFβ signaling components, playing a role in tissue repair processes (Syafruddin2020Two). These interactions highlight KLF6's multifaceted role in cellular regulation and its potential impact on cancer therapy.


## References


[1. (Dionyssiou2013Krüppellike) Mathew G Dionyssiou, Jahan Salma, Mariya Bevzyuk, Stephanie Wales, Lusine Zakharyan, and John C McDermott. Krüppel-like factor 6 (klf6) promotes cell proliferation in skeletal myoblasts in response to tgfβ/smad3 signaling. Skeletal Muscle, April 2013. URL: http://dx.doi.org/10.1186/2044-5040-3-7, doi:10.1186/2044-5040-3-7. This article has 39 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/2044-5040-3-7)

[2. (DiFeo2009The) Analisa DiFeo, John A. Martignetti, and Goutham Narla. The role of klf6 and its splice variants in cancer therapy. Drug Resistance Updates, 12(1–2):1–7, February 2009. URL: http://dx.doi.org/10.1016/j.drup.2008.11.001, doi:10.1016/j.drup.2008.11.001. This article has 102 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.drup.2008.11.001)

[3. (KremerTal2004Frequent) Sigal Kremer-Tal, Helen L. Reeves, Goutham Narla, Swan N. Thung, Myron Schwartz, Analisa Difeo, Amanda Katz, Jordi Bruix, Paulette Bioulac-Sage, John A. Martignetti, and Scott L. Friedman. Frequent inactivation of the tumor suppressor kruppel-like factor 6 ( klf6 ) in hepatocellular carcinoma. Hepatology, 40(5):1047–1052, November 2004. URL: http://dx.doi.org/10.1002/hep.20460, doi:10.1002/hep.20460. This article has 115 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/hep.20460)

[4. (Calderon2012Liganddependent) Mario R. Calderon, Mark Verway, Beum-Soo An, Analisa DiFeo, Tarek A. Bismar, David K. Ann, John A. Martignetti, Tali Shalom-Barak, and John H. White. Ligand-dependent corepressor (lcor) recruitment by krüppel-like factor 6 (klf6) regulates expression of the cyclin-dependent kinase inhibitor cdkn1a gene. Journal of Biological Chemistry, 287(12):8662–8674, March 2012. URL: http://dx.doi.org/10.1074/jbc.M111.311605, doi:10.1074/jbc.m111.311605. This article has 51 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M111.311605)

[5. (Benzeno2004CyclinDependent) Sharon Benzeno, Goutham Narla, Jorge Allina, George Z. Cheng, Helen L. Reeves, Michaela S. Banck, Joseph A. Odin, J. Alan Diehl, Doris Germain, and Scott L. Friedman. Cyclin-dependent kinase inhibition by the klf6 tumor suppressor protein through interaction with cyclin d1. Cancer Research, 64(11):3885–3891, June 2004. URL: http://dx.doi.org/10.1158/0008-5472.can-03-2818, doi:10.1158/0008-5472.can-03-2818. This article has 123 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-03-2818)

[6. (Rodríguez2010NucleoCytoplasmic) Estefanía Rodríguez, Nana Aburjania, Nolan M. Priedigkeit, Analisa DiFeo, and John A. Martignetti. Nucleo-cytoplasmic localization domains regulate krüppel-like factor 6 (klf6) protein stability and tumor suppressor function. PLoS ONE, 5(9):e12639, September 2010. URL: http://dx.doi.org/10.1371/journal.pone.0012639, doi:10.1371/journal.pone.0012639. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0012639)

[7. (Liang2014Identification) Wei-Cheng Liang, Yan Wang, Li-Jia Xiao, Yu-Bing Wang, Wei-Ming Fu, Wei-Mao Wang, Hui-Qing Jiang, Wei Qi, David Chi-Cheong Wan, Jin-Fang Zhang, and Mary Miu-Yee Waye. Identification of mirnas that specifically target tumor suppressive klf6-fl rather than oncogenic klf6-sv1 isoform. RNA Biology, 11(7):845–854, June 2014. URL: http://dx.doi.org/10.4161/rna.29356, doi:10.4161/rna.29356. This article has 38 citations and is from a peer-reviewed journal.](https://doi.org/10.4161/rna.29356)

[8. (Andreoli2010Biology) Verónica Andreoli, Ricardo C. Gehrau, and Jose Luis Bocco. Biology of krüppel‐like factor 6 transcriptional regulator in cell life and death. IUBMB Life, 62(12):896–905, December 2010. URL: http://dx.doi.org/10.1002/iub.396, doi:10.1002/iub.396. This article has 72 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/iub.396)

[9. (Syafruddin2020Two) Saiful Syafruddin, M. Mohtar, Wan Wan Mohamad Nazarie, and Teck Low. Two sides of the same coin: the roles of klf6 in physiology and pathophysiology. Biomolecules, 10(10):1378, September 2020. URL: http://dx.doi.org/10.3390/biom10101378, doi:10.3390/biom10101378. This article has 47 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/biom10101378)

[10. (Jeng2003KLF6) Yung‐Ming Jeng and Hey‐Chi Hsu. Klf6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. International Journal of Cancer, 105(5):625–629, March 2003. URL: http://dx.doi.org/10.1002/ijc.11123, doi:10.1002/ijc.11123. This article has 70 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/ijc.11123)

[11. (Sangodkar2009Functional) Jaya Sangodkar, Jiayan Shi, Analisa DiFeo, Rachel Schwartz, Romina Bromberg, Aisha Choudhri, Kim McClinch, Raheleh Hatami, Elias Scheer, Sigal Kremer-Tal, John A Martignetti, Alex Hui, W.K. Leung, Scott L. Friedman, and Goutham Narla. Functional role of the klf6 tumour suppressor gene in gastric cancer. European Journal of Cancer, 45(4):666–676, March 2009. URL: http://dx.doi.org/10.1016/j.ejca.2008.11.009, doi:10.1016/j.ejca.2008.11.009. This article has 44 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.ejca.2008.11.009)